tiprankstipranks
Medical System Network Co., Ltd. (JP:4350)
:4350
Japanese Market

Medical System Network Co., Ltd. (4350) AI Stock Analysis

0 Followers

Top Page

JP:4350

Medical System Network Co., Ltd.

(4350)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 5.2)
Rating:70Outperform
Price Target:
¥594.00
▲(14.01% Upside)
Action:UpgradedDate:10/18/25
The stock of Medical System Network Co., Ltd. scores well due to its solid financial performance and attractive valuation. While technical indicators suggest a neutral trend, the reasonable P/E ratio and dividend yield enhance its investment appeal. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Consistent revenue growth
Multi-year revenue growth indicates durable demand for the company's hospital and clinic services and strengthens its market position. Sustained top-line expansion supports operating leverage, funding for product/service improvements and predictable cash generation over the medium term.
Negative Factors
Declining free cash flow and margins
Falling free cash flow and thinner net margins reduce internal funds available for capex, innovation and shareholder returns. If sustained, margin pressure can constrain strategic investments, necessitate external financing, and weaken the company's ability to compete on product and service development.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent revenue growth
Multi-year revenue growth indicates durable demand for the company's hospital and clinic services and strengthens its market position. Sustained top-line expansion supports operating leverage, funding for product/service improvements and predictable cash generation over the medium term.
Read all positive factors

Medical System Network Co., Ltd. (4350) vs. iShares MSCI Japan ETF (EWJ)

Medical System Network Co., Ltd. Business Overview & Revenue Model

Company Description
Medical System Network Co., Ltd. distributes pharmaceutical products for pharmacies, hospitals, clinics, and pharmaceutical wholesalers. The company operates through Community Pharmacy Network, Leasing and Facility-related, Meal Catering, and Othe...
How the Company Makes Money
null...

Medical System Network Co., Ltd. Financial Statement Overview

Summary
Medical System Network Co., Ltd. demonstrates solid financial health with consistent revenue growth and stable profitability. The balance sheet shows a strong equity position, though recent declines in free cash flow and net income margins indicate areas for improvement.
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
68
Positive
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue124.07B122.39B115.36B109.55B106.69B104.26B
Gross Profit51.41B49.60B47.93B45.92B44.43B42.41B
EBITDA6.48B6.42B6.90B6.25B7.05B7.18B
Net Income1.17B1.26B1.86B1.61B2.39B2.20B
Balance Sheet
Total Assets71.78B70.63B68.19B66.27B62.98B64.49B
Cash, Cash Equivalents and Short-Term Investments8.74B8.46B8.27B8.14B8.20B10.12B
Total Debt25.01B29.79B29.18B30.52B29.57B32.56B
Total Liabilities55.52B54.28B52.97B51.78B49.69B53.30B
Stockholders Equity16.16B16.26B15.17B14.45B13.27B11.16B
Cash Flow
Free Cash Flow0.001.75B5.62B3.37B1.88B3.68B
Operating Cash Flow0.004.46B7.72B4.97B4.01B5.21B
Investing Cash Flow0.00-3.73B-3.65B-2.11B-2.51B-1.49B
Financing Cash Flow0.00-544.00M-3.94B-2.92B-3.42B-5.31B

Medical System Network Co., Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price521.00
Price Trends
50DMA
519.59
Positive
100DMA
512.74
Positive
200DMA
492.63
Positive
Market Momentum
MACD
9.58
Negative
RSI
56.45
Neutral
STOCH
65.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4350, the sentiment is Positive. The current price of 521 is below the 20-day moving average (MA) of 527.95, above the 50-day MA of 519.59, and above the 200-day MA of 492.63, indicating a bullish trend. The MACD of 9.58 indicates Negative momentum. The RSI at 56.45 is Neutral, neither overbought nor oversold. The STOCH value of 65.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4350.

Medical System Network Co., Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
¥16.27B6.832.32%6.60%27.97%
69
Neutral
¥453.20B14.0511.37%3.04%6.32%8.19%
67
Neutral
¥357.89B16.820.41%15.81%27.05%
66
Neutral
¥665.13B14.4415.71%0.96%21.81%67.76%
62
Neutral
¥979.56B19.411.72%
60
Neutral
¥511.03B22.790.93%3.73%18.84%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4350
Medical System Network Co., Ltd.
539.00
131.67
32.32%
JP:9989
Sundrug Co
3,876.00
-507.11
-11.57%
JP:7649
Sugi Holdings Co
3,529.00
501.97
16.58%
JP:3391
TSURUHA Holdings
2,177.50
41.19
1.93%
JP:3349
COSMOS Pharmaceutical Corporation
6,420.00
-1,643.88
-20.39%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,743.00
555.88
17.44%

Medical System Network Co., Ltd. Corporate Events

Medical System Network Grows Sales but Faces Profit Pressure in Q3 FY2026
Feb 13, 2026
Medical System Network Co., Ltd. reported that its pharmacy support businesses, including the pharmaceutical network, are steadily expanding, with a growing number of pharmacies using its services and new community pharmacies opened in the previou...
Medical System Network Posts Higher Sales but Lower Profits for Nine-Month Period, Keeps Full-Year Outlook
Feb 6, 2026
Medical System Network reported consolidated net sales of ¥98.7 billion for the nine months ended December 31, 2025, a 7.4% year-on-year increase, but profitability weakened, with EBITDA down 3.5%, operating profit down 7.8%, ordinary profit ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 18, 2025